Indication
Peritoneal Neoplasms
12 clinical trials
21 products
1 drug
Product
OregovomabClinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-09-26
Product
PlaceboProduct
CarboplatinProduct
PaclitaxelProduct
Nab-paclitaxelClinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
RelacorilantClinical trial
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical PracticeStatus: Active (not recruiting), Estimated PCD: 2025-06-21
Product
BevacizumabProduct
SGN-B7H4VClinical trial
A Phase 1 Study of SGN-B7H4V in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AB-1015Clinical trial
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2022-02-08
Product
AtezolizumabProduct
PembrolizumabProduct
OlaparibClinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
DocetaxelClinical trial
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2020-12-02
Product
TremelimumabClinical trial
An International Retrospective Observational Study Comparing Primary Cytoreductive Surgery With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Patients With Carcinoma of the Ovary, Fallopian Tubes and PeritoneumStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Neoadjuvant chemotherapyProduct
Adjuvant chemotherapyClinical trial
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerStatus: Recruiting, Estimated PCD: 2028-12-30
Drug
TiragolumabProduct
NilotinibClinical trial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).Status: Recruiting, Estimated PCD: 2025-10-01
Product
LetrozoleClinical trial
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority StudyStatus: Recruiting, Estimated PCD: 2024-08-01